The nation of Zimbabwe has declined a substantial US health deal worth 367 million US dollars (£272m) spanning five years over the United States' request for confidential biological samples.
This rejection came to light after a government memo from December was disclosed, which showed Head of State Emmerson Mnangagwa felt the deal was "lopsided".
An official representative has since clarified that the US was demanding access to biological samples for research and commercial purposes but refused to guarantee the resulting advantages from future medical innovations.
"We are forced to start the challenging and unfortunate task of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had furnished over $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged more talks to secure a agreement acceptable to both sides so the country's critical HIV treatment initiative can be sustained.
Broader Context
Zimbabwe's decision follows a similar case in Kenya, where a high court suspended a similar deal with the US following concerns were raised about the security of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had managed aid for the US government, but Trump stated its expenditure was "wasteful" and his government was seeking direct bilateral deals to enhance transparency and accountability.
As per statements, 16 nations in Africa have to date agreed to these new health pacts, representing more than $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration would have delivered immense benefits for Zimbabwean communities, especially the 1.2 million currently on HIV treatment through American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to share its biological resources and data for a long time, without any corresponding promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"In essence, our nation would provide the basic resources for medical research with no certainty that the resulting innovations would be available to our people if a future disease outbreak arise."
Sovereignty and Global Health
He also pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral deals were undermining systems already established via the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to manage potential global health emergencies.
"This mechanism is designed to ensure that when a country contributes its data, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to develop them."
The government's concerns over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage continued dialogue with our American counterparts on how subsequent co-operation could be structured in a manner that honours the independence and dignity of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the government's concerns, but recommended that talks need to persist since much of the country's HIV programmes were funded by foreign aid.
"If specific concerns exist, such as those relating to information security or agreement terms, these can frequently be addressed through technical clarification and mutually agreed protections," it said.
The halted deal emphasises the continuing challenges between accepting crucial foreign assistance and protecting national sovereignty in an ever more interconnected world.